VISTECH grant for Anadis
Tuesday, 01 July, 2008
Melbourne's Anadis (ASX: ANX) has been awarded a significant grant from VISTECH for its alimentary mucositis treatment.
The grant is one of only three awarded from VISTECH, a bi-national fund granted by the Victorian and the Israeli Governments, and was awarded through a competitive process including a vigorous scientific assessment.
The US$500,000 grant was awarded to Anadis and its Israeli collaborator Maya BioTech. The money will be used to help fund a clinical trial of polyclonal antibodies, which is expected to take between 18-24 months.
Anadis is predicting to be able to launch a commercial product in as little as two years.
Gastro-intestinal and oral mucositis is a significant side effect of cancer therapy.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
